)
Aurobindo Pharma has received the final approval from the US Food & Drug Administration(US FDA) to manufacture and market extended Phenytoin Sodium Capsules, an anti-epileptic drug for controlling seizures.
The approved generic product is bioequivialent and therapeutically equivalent to the reverence listed drug product Dilantin of Parke-Davvis Division of Pfizer In, according to a statement issued by the company on Monday. The product had an estimated market size of $ 125 million for the twelve months ending April, 2015, Aurobindo said.
